Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 20/20 | 0.61 |
| ▸ | HSP90AB1 | P08238 | 11/20 | 0.61 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.41 |
| ▸ | TRAP1 | Q12931 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14177804 | 0.84 | HSP90AA1 (0.40) | HSP90AA1HSP90AB1 | |
| SCHEMBL4581830 | 0.83 | HSP90AA1 (0.41) | HSP90AA1HSP90AB1 | |
| SCHEMBL4581937 | 0.80 | HSP90AA1 (0.60) | HSP90AA1HSP90AB1 | |
| SCHEMBL4581868 | 0.79 | HSP90AA1 (0.64) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL1220501 | 0.76 | HSP90AB1 (1.00) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL422561 | 0.71 | HSP90AA1 (0.85) | HSP90AA1 | |
| SCHEMBL3634060 | 0.71 | HSP90AA1 (0.90) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL5005048 | 0.71 | HSP90AA1 (0.90) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL5004732 | 0.71 | HSP90AA1 (0.90) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL17848239 | 0.70 | ALK (0.53) | HSP90AA1HSP90AB1HSP90B1TRAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119457-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-05-22 | — | — | US | claimed |
| US-20080119457-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080119457-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080119457-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-05-22 | — | — | US | disclosed |
| WO-2008024978-A2 | TETRAHYDROINDOLONE AND TETRAHYDROINDAZOLONE DERIVATIVES | SERENEX, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008024978-A2 | TETRAHYDROINDOLONE AND TETRAHYDROINDAZOLONE DERIVATIVES | SERENEX, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119457-A1 | Benzene, Pyridine, and Pyridazine Derivatives | MKI67, CCNB1, RB1 | HSP90AA1 2260/4885HSP90AB1 1548/4885HSP90B1 2483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.